Laura Connelly Smith
Hematology · Seattle, WANPI 1346525979
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,300 of the $3,875 with a category attached, or 85.2%. Omeros Corporation accounts for 61.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $2,400 and has fallen 76.0% since, to $575 in 2023.
Across 3 payments — averaging $1291.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omeros Corporation$2K
- AstraZeneca$900
- National Marrow Donor Program$575
Across 6 payments — averaging $63,217 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$377K
- Incyte Corporation$2K
What the payments were for
- Consulting fees$3,30085%
- Speaking & faculty fees$57515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omeros Corporation | 1 | $2,400 |
| AstraZeneca | 1 | $900 |
| National Marrow Donor Program | 1 | $575 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$900
How this compares
$3,875 in reported general payments places this provider in the 65th percentile of 43 hematology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 37 | $470,758 |
| RezurockBelumosudil Mesylate | 13 | $220,508 |
| EliquisApixaban | 35 | $21,515 |
| ValacyclovirValacyclovir Hcl | 53 | $2,019 |
| Sirolimus | 12 | $953 |
| Hydrocortisone | 18 | $844 |
| Acyclovir | 61 | $639 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $617 |
| Mycophenolate Mofetil | 14 | $577 |
| Prednisone | 38 | $388 |
| Losartan Potassium | 31 | $386 |
| Penicillin V Potassium | 28 | $344 |
| Pantoprazole Sodium | 43 | $290 |
| Potassium Chloride | 14 | $269 |
| Levothyroxine Sodium | 24 | $196 |
Paid to pharmacies, not to this prescriber.
Other hematology in Seattle
- Barbara KonkleSeattle$250K
- Terry GernsheimerSeattle$148K
- Sandhya PanchSeattle$140K
- Roland WalterSeattle$92K
- Cecilia YeungSeattle$42K
- Kleber Yotsumoto FertrinSeattle$29K
- Jordan GauthierSeattle$17K
- David NgSeattle$9K
- Jose LopezSeattle$8K
- Geoffrey HillSeattle$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.